Bisphosphonates, bone, and breast cancer recurrence
Bisphosphonates reduce bone turnover by inhibiting osteoclast maturation and function, and are important in the prevention of age-related osteoporosis and bone fracture, 1 in the prevention of complications of bone metastases, 2 and in the prevention of osteopenia and osteoporosis resulting from adjuvant aromatase inhibitor therapy of breast cancer. 3 Over 125 years ago, in The Lancet, Paget hypothesised that the "soil" in which a tumour resides would be important for tumour propagation and growth. 4 Interruption of the interaction of tumour micrometastases with their microenvironmental "soil" is now a subject of intense investigation. Bone is an active microenvironment, and, in bone with high turnover, excess osteoclastic activity could potentially lead to excess production of growth factors, which could aff ect survival of micrometastases. 5 Bisphosphonates, by reducing osteoclast activity, could in theory reduce expression of these factors, thereby preventing establishment of micrometastatic disease.
Clinical trials of bisphosphonates as adjuvant therapy for breast cancer have had mixed results. Clodronate, an oral fi rst-generation bisphosphonate, showed a disease-free survival benefi t versus placebo in one large randomised trial, 6 but not in another. 7 An early trial of zoledronic acid, a more powerful third-generation aminobisphosphonate, added to adjuvant aromatase inhibitor therapy for postmenopausal women to prevent bone loss, showed a non-signifi cant improve ment in disease-free survival, 3 a secondary endpoint. Larger trials comparing zoledronic acid to no therapy in postmenopausal women, 8 or in premenopausal women made menopausal with gonadotropin-releasing hormone agonists, 9 showed signifi cant disease-free survival benefi ts, but no benefi t was seen in a large randomised trial of both premenopausal and postmenopausal women. 10 In The Lancet, the Early Breast Cancer Trialists' Collaborative Group 11 presents a meta-analysis of randomised trials of bisphosphonates as adjuvant systemic therapy for breast cancer. This meta-analysis is comprised of individual patient data derived from randomised adjuvant bisphosphonate trials in breast cancer done over the past 20 years. The analysis received data on 18 766 women (18 206 in randomised trials of 2-5 years of adjuvant bisphosphonate vs control), with a median follow-up of 5·6 years, 3453 fi rst recurrences, and 2106 deaths. For all patients, there were borderline signifi cant reductions with the addition of bisphosphonates at 10 years for distant recurrence (20·4% vs 21·8%, rate ratio [RR]=0·92, 95% CI 0·85-0·99; 2p=0·03), bone recurrence (7·8% vs 9·0%, RR=0·83, 0·73-0·94; 2p=0·004), breast cancer mortality (16·6% vs 18·4%, RR=0·91, 0·83-0·99; 2p=0·04), and all-cause mortality (20·8% vs 22·3%, RR=0·92, 0·85-1·00; 2p=0·06). In postmenopausal women, there were highly signifi cant reductions with the addition of bisphosphonates at 10 years for bone recurrence (6·6% vs 8·8%, RR=0·72, 0·60-0·86; 2p=0·0002) and for breast cancer mortality (14·7% vs 18·0%, RR=0·82, 0·73-0·93; 2p=0·002). This benefi t was independent of the type of bisphosphonate, the schedule of bisphosphonate administration, the oestrogen receptor status of the primary tumour, the presence of axillary lymph node involvement, and the use of concomitant systemic chemotherapy. There was no reduction in the incidence of contralateral breast cancer or in the risk of metastasis to non-osseous sites. In the 13 341 women with available fracture data, bisphosphonates reduced the risk of fracture from 7·3% to 6·3% (RR=0·85, 0·75-0·97; 2p=0·02). This landmark report on breast cancer treatment should lead to widespread adoption of bisphosphonates as a standard of care for the adjuvant therapy of early-stage breast cancer in postmenopausal women. The absolute reduction in the risk of breast cancer death at 10 years with the use of bisphosphonates in postmenopausal women (3·3%) is similar to the benefi t seen with anthracycline polychemotherapy versus nonanthracycline poly chemotherapy. 12 Bisphosphonates, in one form or another, are generic and relatively inexpensive in most parts of the world. The toxic eff ects of these agents are relatively mild (ie, gastrointestinal upset, arthralgias, and very uncommon osteonecrosis of the jaw). 6, 10 All bisphosphonates appear to be eff ective, as long as they are given for at least 2 years. Given their low cost, relatively low toxicity, and overall survival benefi t, widespread use of adjuvant bisphosphonates for postmenopausal breast cancer has great potential to reduce mortality from this disease further.
Should all postmenopausal women with early-stage breast cancer receive adjuvant bisphosphonates? Bisphosphonate action seems to be bone centric, in that bisphosphonates do not appear to prevent contralateral breast cancer, locoregional disease, or metastases to non-osseous sites. A recent report 13 indicating that overexpression of lysyl oxidase by primary breast cancers can lead to increased bone turnover in the bone microenvironmental niche and increased establishment of bone metastases is intriguing, and suggests a potential biomarker for response. Increased bone turnover after menopause might also explain the preferential benefi t of bisphosphonates in reducing bone recurrence in post menopausal women. It will be interesting to determine if osteoprotogerin analogues such as denosumab provide disease-free survival benefi ts similar to bisphosphonates in ongoing clinical trials such as ABCSG-18, 14 in which denosumab signifi cantly reduced fracture rates in post menopausal women receiving aromatase inhibitors.
This apparent success in altering the natural history of breast cancer by modifying the tumour micro environment lends great credence to investigational eff orts in breast cancer and other cancers attempt ing to understand and modify tumour-host micro environmental interactions.
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